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ABSTRACT
Inducing stable control of tumour growth by tumour reversion is an alternative 
approach to cancer treatment when eradication of the disease cannot be achieved. 
The process requires re-establishment of normal control mechanisms that are 
lost in cancer cells so that abnormal proliferation can be halted. Embryonic 
environments can reset cellular programmes and we previously showed that axolotl 
oocyte extracts can reprogram breast cancer cells and reverse their tumorigenicity. 
In this study, we analysed the gene expression profiles of oocyte extract-treated 
tumour xenografts to show that tumour reprogramming involves cell cycle arrest 
and acquisition of a quiescent state. Tumour dormancy is associated with increased 
P27 expression, restoration of RB function and downregulation of mitogen-
activated signalling pathways. We also show that the quiescent state is associated 
with increased levels of H4K20me3 and decreased H4K20me1, an epigenetic 
profile leading to chromatin compaction. The epigenetic reprogramming induced 
by oocyte extracts is required for RB hypophosphorylation and induction of P27 
expression, both occurring during exposure to the extracts and stably maintained 
in reprogrammed tumour xenografts. Therefore, this study demonstrates the value 
of oocyte molecules for inducing tumour reversion and for the development of new 
chemoquiescence-based therapies.
INTRODUCTION
Cancer is a disease characterised by abnormal cell 
proliferation and first line treatments aim to eradicate 
tumour growth and metastatic spread. Novel therapies 
are being developed to specifically target molecular 
mechanisms at the basis of tumorigenesis to affect 
oncogenic pathways [1, 2]. However, they do not target all 
the molecular alterations that contribute to the complexity 
of the disease and they often result in drug resistance by 
allowing regrowth of tumour clones that do not respond 
to treatment [3]. Another approach to the development of 
targeted therapies is studying the mechanisms of tumour 
reversion, a biological process by which tumour cells 
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lose or escape their malignant phenotype [4]. Tumour 
reversion can be induced by environmental cues with 
cells losing their malignant state following induction of 
growth arrest, apoptosis or differentiation [4]. Different 
models of tumour reversion have been explored and 
critical genes include a number already identified as 
targets of established drugs that could be repurposed for 
cancer treatment [5]. However, because tumour reversion 
involves multiple genes [6], a full understanding of its 
complexity still needs to be realised.
Among tumour reversion models, embryonic 
environments present unique opportunities due to their 
intrinsic ability to epigenetically program cellular states 
during development [7]. Embryos of different species have 
been used to suppress tumorigenicity of cancer cells and this 
approach was extended to embryonic stem cell extracts [8]. 
Indeed, teratocarcinoma cells can be reprogrammed when 
injected into blastocysts and contribute to normal tissue of 
chimeric mice [9]. In addition, injections into embryos of 
different species including zebrafish, chicken and mouse 
have been shown to reduce tumorigenicity and metastasis 
of melanoma cells [10–12]. Studies based on tumour 
reversion with these systems demonstrated that cancer 
cells retain a level of plasticity and are able to respond 
to embryonic signals that can induce loss of malignant 
phenotypes and/or growth arrest. Cancer cell plasticity 
can also be exploited for tumour reversion by nuclear 
reprogramming, an epigenetic process involving the change 
of one cellular state into another [13, 14]. Nuclear transfer 
experiments with somatic cells have shown that oocytes are 
able to reprogram somatic chromatin with remodelling of 
histone variants, histone modifications, DNA methylation 
and incorporation of oocyte-specific factors which actively 
participate in the reprogramming process [15–18]. The 
ability of oocytes to mediate tumour reversion has been 
further confirmed by ex ovo reprogramming experiments 
using extracts from amphibian and mammalian oocytes [19, 
20]. Among amphibians, axolotls are unique experimental 
models because the molecular mechanisms regulating 
early development of axolotls and mammals are conserved 
[21–23]. Axolotl oocytes are very large and available 
in significant quantities, thus representing a unique 
experimental system for biochemical studies. We have 
previously introduced the value of axolotl oocyte extracts 
in tumour reversion and showed that they can reprogram 
breast cancer cells and suppress tumour growth in vivo [20].
In this study, we extended our investigation of 
tumour reversion with axolotl oocyte extracts by analysing 
the molecular profile of tumour-reverted mouse xenografts 
to show that oocyte-mediated reprogramming of breast 
cancer cells induces growth suppression by cell cycle 
arrest and induction of cellular dormancy. The growth 
arrest is associated with the upregulation of the cell cycle 
inhibitor P27, inhibition of RB phosphorylation and of 
key signalling pathways involved in cell proliferation. 
Growth arrested tumours demonstrated extensive 
epigenetic reprogramming with increased H4K20me3 and 
reduced H4K20me1, which are hallmarks of quiescence. 
Importantly, we show that the program of tumour 
reversion and tumour dormancy is initiated during the 
treatment with the oocyte extracts and is stably maintained 
in xenograft tumours over time.
RESULTS
Reprogrammed tumours show decreased 
proliferation associated with cell cycle arrest
Axolotl oocyte extracts (AOE) can reprogram breast 
cancer cells by reverting tumorigenicity in vivo [20]. In 
this study, we sought to identify the molecular mechanisms 
involved in reverting the tumour phenotype after treatment 
of breast cancer cells with AOE. We therefore determined 
the gene expression profile of tumour xenografts obtained 
from cells treated with AOE, as well as from untreated 
(UN) control cells. Microarray analyses revealed a total 
of 1976 differentially expressed genes, 741 and 1235 up-
regulated and down-regulated in AOE-treated tumours, 
respectively (Figure 1A). Several biological processes 
associated with regulation of cell proliferation were 
identified by Gene Ontology (GO) analysis. RNA splicing 
and processing, chromosome organisation, cell cycle, 
intracellular transport, G coupled receptor signalling were 
significantly represented in the upregulated genes, whereas 
protein translation, protein targeting to membrane, rRNA 
processing, mRNA and cell metabolism were among the 
most significant in the downregulated genes (Figure 1B). 
The interaction between genes that were differentially 
expressed in AOE-treated tumours was also explored 
by mapping to gene networks identified by Ingenuity 
Pathway Analysis (IPA). Developmental disorder and 
metabolic disease, post-translational modification and 
cellular organisation, lipid metabolism, DNA replication 
and repair, cell death and cell growth/survival, and cell 
signalling were among the top networks identified. 
The top molecular and cellular functions also included 
protein synthesis, RNA post-translational modification, 
gene expression, cell growth and proliferation, and cell 
death and survival among the processes affected by the 
cancer cell reprogramming (Supplementary Figure 1A). 
IPA analysis showed Mitochondrial dysfunction and Cell 
cycle: G1/S checkpoint regulation as the most significant 
among the best match canonical pathways (Figure 1C). 
The latter pathway also demonstrated one of the highest 
gene ratios, indicating a high number of genes from the 
dataset represented in the total number of genes involved in 
this pathway. Consistent with this, genes involved in DNA 
replication and repair were found to be downregulated. 
These included members of the origin recognition complex 
assembly (MCM2, MCM5, CDT1), and DNA polymerases 
(POLA1, POLD2, POLD4) (Supplementary Figure 
1B). Several important cell cycle regulators were found 
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differentially expressed in the reprogrammed tumours, 
including CDK4, E2F5, and CDKN1B (P27), WEE1, 
CDKN3 (Figure 1D). The canonical pathway analysis 
revealed additional cell cycle regulators that could be 
potentially involved, including antiproliferative BTG/TOB 
proteins, TGF-β, EIF2, mTOR Integrin and RHO signalling 
proteins (Supplementary Table 1). Differential expression 
of critical cell cycle genes was validated by via qRT-PCR, 
demonstrating the biological relevance of this pathway in 
the tumour-reverted phenotype (Figure 1D).
Figure 1: Gene expression analysis of AOE-reprogrammed tumour xenografts. (A) Volcano plot of differentially expressed 
gene in AOE-treated versus untreated (UN) tumour xenografts. Differentially expressed genes were determined with a cut-off for adjusted 
p-value established at 0.05 and fold change value at ± 2 (n=6). Red dots show genes which are diffrerentially expressed above a 2-fold 
threshold. The part of the graft on the left of the zero point represents genes which are downregulated in AOE-treated tumours (1235), 
whereas the one on the right represents genes which are upregulated in AOE-treated tumours (741). (B) Bar plot ranking the enrichment 
score of GO biological processes for upregulated and downregulated genes in AOE-treated tumours compared to untreated. (C) Best 
match canonical pathway by IPA. Functional pathways are presented in descending order of significance (p<0.05, with threshold specified 
by yellow dotted line). The yellow graph line indicates the ratio between the numbers of genes from the dataset and the total number of 
genes involved in those pathways. (D) Fold change in gene expression as determined by microarray analysis (left) and TaqMan® qRT-PCR 
(right). Quantitative RT-PCR results for each gene are presented as relative fold expression to RPLP0 and the UN group used as calibrator 
(n=3). Relative fold expression levels were analysed by unpaired Student’s t-test. **p< 0.01. Green and red bars indicate downregulated or 
upregulated genes in AOE, respectively.
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Extract-induced cell cycle arrest is associated 
with increased CDKN1B (P27) expression and 
inactivation of RB function
To functionally validate the involvement of a cell 
cycle block we next conducted a BrdU labelling experiment 
of xenografts obtained from reprogrammed cancer cells 
(Supplementary Figure 2). Reprogrammed tumour 
xenografts showed reduced staining of the proliferation 
markers BrdU and Ki67, indicating a cell cycle block before 
S phase (Figure 2A, 2B). In addition, the same tumours 
showed increased expression of P27, which is consistent 
with the observed increased gene expression. Importantly, 
P27 staining was also nuclear in the reprogrammed 
tumours, suggesting its re-established function as tumour 
suppressor after the reprogramming (Figure 2C). As many 
pathways regulating G1-S cell cycle progression converge 
on the activity of the retinoblastoma tumour suppressor 
protein (RB), we next investigated the regulation of RB 
phosphorylation in reprogrammed tumours.
Consistent with cell cycle arrest and the inhibition 
of CDK activity, reprogrammed tumours showed reduced 
phosphorylation of RB at Ser780 (Figure 3A), but not at 
Ser807 or altered expression of total RB levels (Figure 3B, 
3C). Phosphorylation of RB at Ser795 was not detected in 
either untreated or untreated xenografts (Supplementary 
Figure 3A). Hypo-phosphorylation of RB at Ser780 is 
consistent with the observed decreased CDK4 expression 
and the predicted negative z-score of the EIF2 canonical 
signalling pathway. These results further indicate a growth 
arrest phenotype resulting from active RB and inhibition 
of the progression through S and G2/M phases of the cell 
cycle (Supplementary Table 1).
In order to understand whether a cell cycle block 
might be an immediate response to extract treatment, we 
measured RB phosphorylation and P27 expression in treated 
cells at 6 hours and 12 hours after reprogramming, the latter 
representing the same time point at which the cells were 
injected in immunocompromised mice. Phosphorylation 
of RB and its nuclear localisation was reduced by 6 hours 
and this was maintained at low levels up to 12 hours after 
extract treatment (Figure 3D). On the other hand, expression 
of CDKN1B (P27) did not increase immediately after the 
extract treatment (6 hours), but it was induced by 12 hours 
after reprogramming (Figure 3E). These results indicate 
that the induction of cell cycle arrest occurs during the 
reprogramming process in oocyte extracts and it is stably 
maintained in treated tumour xenografts.
Reprogrammed tumours show reduced MAPK 
signalling
In order to elucidate the contribution of cell 
cycle extrinsic regulation in oocyte-mediated cancer 
reprogramming, several signalling pathways involved in 
cell proliferation were analysed.
Reprogrammed tumours demonstrated reduced 
phosphorylation of p44/42 MAPK and SAPK/JNK 
(Figure 4A, 4B), whereas no activation of p38 MAPK was 
observed in either untreated or reprogrammed tumours 
(Supplementary Figure 3B). The downregulation of ERK 
signalling in AOE-treated tumours was also consistent 
with reduced expression of several ERK signalling related 
genes, as identified by GO analysis of the microarray data. 
Indeed, significant down-regulation of MAPK3, MAP2K2, 
MAPKAPK3, ELK1 and up-regulation of the phosphatase 
DUSP1 was found in the reprogrammed tumours (Figure 
4C). We next investigated whether the reduced activation 
of protein kinase signalling occurred immediately after 
the reprogramming or as long-term consequence of the 
extract treatment in tumour xenografts. We detected a 
reduction in expression of the early response genes JUN, 
but not FOS (Figure 4D) and an inhibition of p44/42 
MAPK and p38MAPK after 6 hours reprogramming, 
but no change was found in JNK signalling (Figure 4E). 
Therefore, these data indicate inhibition of mitogen 
activated kinase signalling is an immediate consequence 
of the reprogramming process that is stably maintained in 
reverted tumours. Consistent with our findings, reverted 
tumours showed upregulated expression of MAPK9 
expression (Figure 4C), a negative regulator of JUN [24].
Reprogramming with oocyte molecules induces a 
state of quiescence in cancer cells
We next asked whether the growth/proliferation 
arrest in reprogrammed tumours was associated with 
increased programmed cell death. Reprogrammed 
xenografts did not show any increase in caspase 3 
activation (Figure 5A). Upregulation of the anti-apoptotic 
genes BCL2L2, BAG3, and downregulation of pro-
apoptotic genes DAXX, FAF1, PAK1, DFFA, ENDOG 
was found in reprogrammed tumours pointing to a cell 
cycle arrest without engagement of the apoptotic pathway 
(Figure 5B). DNA damage response and repair pathways 
were also downregulated in reprogrammed tumours 
(Figure 5B).
To ascertain whether the growth-arrested tumours 
sustained long-term survival in a quiescent or senescent 
state, we next investigated signalling pathways that 
coordinate metabolic homeostasis in dormant cells. AOE-
treated tumours showed reduced phosphorylation of AKT 
(Figure 6A) and reduced phosphorylation of both p70S6 
kinase and the translation repressor 4E-BP1 (Figure 6B, 
6C). Consistent with this, inhibition of protein synthesis 
was highlighted by GO analysis, where translation was 
found among the most significant biological processes 
in the down-regulated genes and EIF2 signalling was the 
top canonical pathway with predicted inhibition and a 
negative z-score (Supplementary Table 1).
Altogether, these results suggested a state of tumour 
dormancy. This could also explain the negative regulation 
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of cellular metabolism found in the reprogrammed 
tumours, such as downregulated expression of genes 
involved in glucose metabolism (TPI1, ENO1, ENO2, 
GALM, GPI, GAPDH, PFKP, PGM1, PDHB, PKM2), 
oxidative phosphorylation (ATP5D, UQCRC1, NDUFB9, 
NDUFV1, NDUFS8) and DNA metabolism (NANS, 
UGDH, AMDHD2, MPI, TK1) in AOE-treated tumours. 
An association of these biological functions with the 
downregulated genes was also identified by GO and 
IPA analyses (Figure 1B, Supplementary Figure 1 and 
Supplementary Table 1).
Because our data show that the dormant state 
induced by reprogramming is not associated with a 
response to oncogenic stress and increased mTOR activity 
Figure 2: Quantification of BrdU, Ki67 and P27 staining in AOE-reprogrammed tumours. (A) BrdU staining of UN and 
AOE-treated tumour xenografts. Scatter plot shows the % of positively stained nuclei (n= 3; 6 fields of view). Staining levels were analysed 
by nonparametric Mann-Whitney test. ****p<0.0001. Scale bar = 100μm. (B) Ki67 staining of UN and AOE-treated tumour xenografts. 
Scatter plot shows the % of positively stained nuclei (n= 3-4; 6 fields of view). Staining levels were analysed by nonparametric Mann-
Whitney test. ****p<0.0001. Scale bar = 100μm. (C) P27 staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % of 
positively stained nuclei (n= 4; 6 fields of view). Staining levels were analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale 
bar = 100μm.
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that are characteristics of senescence, we next tested 
whether the lack of cell proliferation in reprogrammed 
tumours could be due to quiescence. Meta-analysis of 
data defining quiescence signatures in cell-cycle arrested 
fibroblasts [25] showed a substantial overlap (~30%) 
with the genes differentially expressed in reprogrammed 
tumours (Figure 7A). GO analysis showed that regulation 
of mRNA metabolic process, cellular component 
organisation and protein transport were among the most 
significant biological processes for the overlapping 
Figure 3: Quantification of RB activation and P27 expression in AOE-reprogrammed tumours and cancer cells. (A) RB 
(Ser780) phosphorylation staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % of positively stained nuclei (n= 4; 6 
fields of view). Staining levels were analysed by nonparametric Mann-Whitney test. ***p<0.001. Scale bar = 100μm. (B) RB (Ser807) 
phosphorylation staining of UN and AOE-treated tumour xenografts. Scatter plot show the % of positively stained nuclei (n= 4; 6 fields of 
view). Staining levels were analysed by nonparametric Mann-Whitney test. p=0.1472. Scale bar = 100μm. (C) Total RB staining of UN and 
AOE-treated tumour xenografts. Scatter plot show the % of positively stained nuclei (n= 3; 5 fields of view). Staining levels were analysed 
by nonparametric Mann-Whitney test. p=0.1485. Scale bar = 100μm. (D) RB (Ser780) phosphorylation staining of UN and AOE-treated 
cells after 6 hours and 12 hours reprogramming. Scatter plot shows the % of positively stained nuclei (n= 2; 5 fields of view). Staining levels 
were analysed by One-way Anova followed by Bonferroni’s multiple comparisons test. ****p<0.0001. Scale bar = 50μm. (E) Fold change in 
P27 (CDKN1B) gene expression as determined by TaqMan® qRT-PCR. Results are presented as relative fold expression to RPLP0 and the 
UN group used as calibrator (n=3). Relative fold expression levels were analysed by Two-way Anova followed by Bonferroni’s multiple 
comparisons test. *p< 0.05.
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up-regulated genes, whereas translation elongation, 
translation termination, rRNA processing, DNA replication 
and repair were the most significant overlapping genes in 
the down-regulated group of genes. Importantly, the key 
regulators of quiescence TOB1, BTG2, THBS1, HES1 
and MLL5 were found in the overlapping genes that were 
upregulated (Figure 7B). Thrombospondin-1 (THBS) 
is an anti-angiogenic factor and endothelium-derived 
Figure 4: Quantification of p44/42 MAPK, SAPK/JNK and p38MAPK activation in AOE-reprogrammed tumours 
and cancer cells. (A) p44/42 MAPK phosphorylation staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % of 
positively stained nuclei (n= 4; 6 fields of view). Staining levels were analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale 
bar = 100μm. (B) SAPK/JNK phosphorylation staining of UN and AOE-treated tumour xenografts. Scatter plot show the % of positively 
stained nuclei (n= 4; 6 fields of view). Staining levels were analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale bar = 100μm. 
(C) Fold change in gene expression as determined by microarray analysis. (D) Fold change in JUN and FOS gene expression as determined 
by TaqMan® qRT-PCR. Results are presented as relative fold expression to RPLP0 and the UN group used as calibrator (n=3). Relative fold 
expression levels were analysed by Two-way Anova followed by Bonferroni’s multiple comparisons test. *p< 0.05. (E) Western blotting 
analysis of p44/42 MAPK, SAPK/JNK and p38MAPK phosphorylation of cells treated with AOE for 6 hours. Relative quantification of 
phosphorylation was calculated as ratio between the levels of phosphorylated and total protein signals. Relative quantification was analysed 
by unpaired Student’s t-test. *p< 0.05.
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tumour suppressor that can sustain breast cancer dormancy 
[26]. BTG proteins are important regulators of cell cycle 
progression [27] and TOB1 acts as a tumour suppressor 
in MCF-7 cells by inducing arrest at G1-S phase through 
upregulation of P27 and decreased activity of ERK2 and 
AKT [28].
Oocyte extract mediated tumour quiescence 
involves epigenetic reprogramming
We next investigated whether the induction of a 
quiescent state in treated tumours depended on epigenetic 
reprogramming, as previous work demonstrated the 
ability of AOE to remodel epigenetic modifications of the 
chromatin in both somatic and cancer cells [20, 29]. We 
therefore first analysed H4K20 histone methylation as this 
modification has been reported to regulate quiescence and 
chromatin compaction [30]. Consistent with an induction 
of quiescence, a significant decrease in the levels of 
H4K20me1 and increase in H4K20me3 were detected in 
reprogrammed tumours (Figure 8). In addition, similarly 
to the epigenetic profile reported in MCF-7 slowly 
proliferating “G0-like” cells [31], a decrease in H3K9me3, 
H3K9me2, H3K27me3 and H3K4me3 was found. Levels of 
active transcription marks H3K9ac and H4K16ac were also 
lower in reprogrammed tumours, confirming a non-cycling 
chromatin configuration (Figure 8). In order to investigate 
the relationship between epigenetic reprogramming and 
cell cycle arrest in the induction of quiescence we next 
studied the dynamics of H4K20 methylation and RB 
phosphorylation immediately after reprogramming. We 
measured a reduction of H4K20me1 and H4K20me3 after 
Figure 5: Quantification of apoptosis and DNA repair pathways. (A) Cleaved Caspase 3staining of UN and AOE-treated tumour 
xenografts. Scatter plot shows the % of positively stained nuclei (n= 3; 6 fields of view). Staining levels were analysed by nonparametric 
Mann-Whitney test. p=0.4197. Scale bar = 100μm. (B) Fold change in apoptosis and DNA repair genes expression as determined by 
microarray analysis (left) and TaqMan® qRT-PCR (right). Quantitative RT-PCR results for each gene are presented as relative fold expression 
to RPLP0 and the UN group used as calibrator (n=3). Relative fold expression levels were analysed by unpaired Student’s t-test. **p< 0.01. 
Green and red bars indicate downregulated or upregulated genes in AOE, respectively.
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6 hours and 12 hours of AOE treatment, in agreement with 
the epigenetic status of reprogrammed tumour xenografts. 
These changes were abolished when cells were incubated 
in extracts pre-treated and supplemented with the PHF8 
inhibitor Daminozide (DAM) and the SUV420H1/H2 
inhibitor A-196, which can prevent the demethylation and 
methylation of H4K20me1, respectively (Figure 9).
This inhibition was most likely due to an effect on 
histone demethylase and methylase enzymes contained 
in the extract as no effect was seen when inhibitors were 
added to control cells incubated in buffer under the same 
experimental conditions. Importantly, the AOE-mediated 
de-phosphorylation of RB did not occur in the presence 
of these epigenetic inhibitors (Figure 10A). Induction 
Figure 6: Quantification of AKT, p70S6K and 4E-BP1 activation in AOE-reprogrammed tumours. (A) AKT 
phosphorylation staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % of positively stained nuclei (n= 4; 6 fields of 
view). Staining levels were analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale bar = 100μm. (B) p70S6K phosphorylation 
staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % of positively stained nuclei (n= 4; 6 fields of view). Staining 
levels were analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale bar = 100μm. (C) 4E-BP1 phosphorylation staining of UN 
and AOE-treated tumour xenografts. Scatter plot shows the % of positively stained nuclei (n= 3; 6 fields of view). Staining levels were 
analysed by nonparametric Mann-Whitney test. ****p<0.0001. Scale bar = 100μm.
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of CDKN1B (P27) expression also was dependent of 
H4K20me remodelling, whereas the reduced expression of 
JUN was not affected (Figure 10B). Therefore, the results 
suggest that the induction of a stable cell cycle arrest 
and associated tumour cellular dormancy depends on 
epigenetic reprogramming mediated by oocyte molecules 
Figure 7: Gene expression signature of quiescence in AOE-reprogrammed tumour xenografts. (A) Meta-analysis of gene 
expression profile of quiescent fibroblasts [25] and differentially expressed genes of AOE-reprogrammed tumours using Venny software. 
Enriched biological processes for overlapping upregulated and downregulated genes are highlighted. (B) Fold change in expression of 
quiescence-related gene in AOE-reprogrammed tumours as determined by microarray analysis (left) and TaqMan® qRT-PCR (right). 
Quantitative RT-PCR results for each gene are presented as relative fold expression to RPLP0 and the UN group used as calibrator (n=3). 
Relative fold expression levels were analysed by unpaired Student’s t-test. **p< 0.01. Red bars indicate upregulated genes in AOE.
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Figure 8: Quantification of histone modifications in AOE-reprogrammed tumours. H4K20me3, H4K20me1, H3K9me3, 
H3K9me2, H3K27me3, H3K9ac, H3K4me3, H4K16ac staining of UN and AOE-treated tumour xenografts. Scatter plot shows the % 
of positively stained nuclei (n= 3-4; 6 fields of view). Staining levels were analysed by nonparametric Mann-Whitney test. **p<0.01, 
***p<0.001, ****p<0.0001. Scale bar = 100μm.
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which promote chromatin compaction and inhibition of 
the cell cycle (Figure 11).
DISCUSSION
The idea of inducing tumour reversion by allowing 
cancer cells to regain control of normal growth has been 
receiving renewed attention [32]. Tumour reversion is 
considered a different approach for the development 
of new treatments based on the selection of stable 
cancer revertants. As a therapeutic strategy, tumour 
reversion can induce tumour differentiation or growth 
arrest by reactivating the normal control mechanisms 
that regulate cell proliferation. In this way, successful 
tumour reversion strategies can allow complete or partial 
stable cancer remission. Tumour reversion has also 
been an important strategy for elucidating of molecular 
mechanisms involved in tumorigenesis. For instance, 
tumour reversion induced by oncolytic viruses or viral 
oncogenes has led to the discovery of novel tumour 
suppressor genes [4, 33–35].
We previously showed that treatment of breast 
cancer cells with axolotl oocyte extracts can induce 
growth arrest both in vitro and in vivo [20]. In this study, 
we sought to identify the molecular mechanisms involved 
in such a growth-arrested phenotype to elucidate whether 
treatment of cancer cells with oocyte extracts could 
provide insight into potential therapeutic targets for 
tumour reversion. By genome-wide screening of reverted 
xenograft tumours we demonstrated that treatment of 
luminal breast cancer cells with oocyte extracts induces 
cell cycle arrest associated with upregulated expression 
of CDKN1B (P27) and reduction of RB phosphorylation. 
CDKN1B is a cell cycle inhibitor that controls the G0 to 
S- phase transition by regulating activity of the cyclin-
dependent kinase (CDK) complexes CyclinD-CDK4 
and CyclinD-CDK6 [36]. Decreased expression of P27 
has been correlated with the development of and poor 
prognosis of breast cancer [37, 38]. Importantly, the oocyte 
extract treatment not only increased the expression of P27 
but also changed its localisation from the cell cytoplasm 
to the nucleus. In quiescent normal cells, functional P27 
Figure 9: H4K20me1 and H4K20me3 staining of untreated and AOE-treated cells in the presence of inhibitors of 
SUV420H1/H2 and PHF8. H4K20me1 and H4K20me3 staining of cells incubated in growth medium (UN) or AOE for 6 hours in the 
presence or absence of Daminozide (DAM) or A-196. Cells were analysed immediately after reprogramming (6 hours) and after overnight 
culture (12 hours). Histogram shows the % of positively stained nuclei (n= 2; 5 fields of view). Staining levels were analysed by Two-way 
Anova followed by Bonferroni’s multiple comparisons test. *p< 0.05. **p<0.01, ****p<0.0001. Scale bar = 50μm.
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Figure 10: RB (Ser780) phosphorylation and expression of JUN and CDKN1B (P27) of untreated and AOE-treated cells 
in the presence of inhibitors of SUV420H1/H2 and PHF8. (A) RB (Ser780) phosphorylation staining of cells incubated in growth 
medium (UN) or AOE for 6 hours in the presence or absence of DAM or A-196. Cells were analysed immediately after reprogramming 
(6 hours) and after overnight culture (12 hours). Histogram shows the % of positively stained nuclei (n= 2; 5 fields of view). Staining 
levels were analysed by One-way Anova followed by Bonferroni’s multiple comparisons test. **p<0.01, ***p<0.001, ****p<0.0001. Scale 
bar = 50μm. (B) Fold change in expression of JUN (6 hours after reprogramming) and P27 (CDKN1B) (12 hours after reprogramming) as 
determined by TaqMan® qRT-PCR. Results are presented as relative fold expression to RPLP0 and the UN group used as calibrator (n=3). 
Relative fold expression levels were analysed by One-way Anova followed by Bonferroni’s multiple comparisons test. ****p< 0.0001.
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has a nuclear localisation, whereas oncogenic activation 
of MAPK promotes its cytoplasmic accumulation, thus 
promoting cell motility and invasion [36]. Therefore, 
restoration of P27 expression and function represents a 
significant effect of oocyte-mediated tumour reversion. 
Consistent with inhibition of the G0/G1-S transition, 
we also measured reduced expression of CDK4 in 
reprogrammed tumours and reduced RB phosphorylation 
at Ser780 (the RB amino acid substrate of the Cyclin D1-
CDK complex) in reprogrammed tumours [39]. In its 
active form, hypophosphorylated RB leads to repression of 
E2F-regulated genes and inhibition of progression through 
S phase and G2/M [40]. Reprogrammed tumours also 
presented reduced phosphorylation of p44/42, a pathway 
implicated in breast cancer growth. Indeed, mutations 
leading to constitutive activation of the p44/42 MAPK 
pathway is common in breast cancer and critical for breast 
cancer progression and invasion [41].
This pathway has been shown to mediate P27 
degradation [42]. In turn, P27 can inhibit MAPK 
activation by sequestering H-Ras [43], suggesting that 
these mechanisms could reduce cell proliferation working 
through a negative feedback loop in AOE treated tumours.
JNK was another downregulated signalling pathway 
in growth arrested AOE-treated tumours. Activation of 
JNK has a suppressive role in mammary carcinogenesis 
by mediating stress-induced apoptosis [44, 45]. One 
unexpected finding in this study was the lack of apoptosis 
following cell cycle arrest induced by AOE treatment, 
which could be due to the inhibition of the observed JNK 
signalling. Suppression of cancer growth is not always 
associated with an apoptotic response, but it can also 
involve an induction of cellular dormancy, a state that 
can consist of either quiescence or senescence. In contrast 
to senescence, which occurs irreversibly in response to 
oncogenic signals and ageing, quiescence is a reversible 
process which is not induced by replicative stress. During 
quiescence cells become G0-G1 arrested due to lack of 
growth factor stimulation, cell adhesion signalling and 
angiogenesis, thus resulting in inhibition of metabolic and 
translational activity [46]. AOE-reprogrammed tumours 
also showed reduced activation of the AKT and mTOR 
pathways, which pointed to a quiescence phenotype, rather 
than senescence. Because quiescent cells demonstrate a 
characteristic gene expression profile which is not a mere 
consequence of cell cycle arrest [47], we overlapped our 
gene set with the quiescence-specific gene expression 
profile of quiescent fibroblasts [25]. The fact that we found 
a significant overlap between gene signatures confirms an 
induction of tumour dormancy after AOE reprogramming. 
Two important epigenetic regulators, MLL5 and HES1 
[48, 49], were identified among the common quiescence-
related genes, suggesting a link between AOE-induced 
growth arrest and epigenetic reprogramming. We 
previously demonstrated that AOE can induce profound 
epigenetic changes both in somatic and cancer cells which 
Figure 11: Pathways crosstalk involved in tumour reversion mediated by oocyte extracts.
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involve remodelling of DNA methylation and histone 
modifications [20, 50]. Therefore, one important question 
to address was the relationship between the cell cycle arrest 
and epigenetic reprogramming mediated by AOE. We 
found that AOE reprogrammed tumours demonstrated an 
extensive epigenetic reprogramming which involved the 
acquisition of a compact chromatin configuration [30]. 
Loss of H4K20me3 is a hallmark of cancer and a prognostic 
factors in breast cancer [51, 52]. Therefore, restoration of 
this chromatin mark is likely to be an important regulator 
of AOE-mediated tumour reversion. We have shown that 
epigenetic reprogramming is initiated during the 6 hours 
treatment of cancer cells with AOE and is maintained up to 
the point when cells are injected into mice. However, this 
reprogramming was halted when inhibitors of epigenetic 
modifiers were used. In addition, the inhibition of the these 
enzymatic activities prevented RB dephosphorylation and 
induction of P27 expression, suggesting that epigenetic 
reprogramming due to chromatin compaction may be 
critical for cell cycle arrest, as previously reported [53]. 
Because the inhibitors did not affect cells that were not 
treated with AOE (control group), we speculated that the 
epigenetic reprogramming may be mediated by enzymatic 
activities present in the oocyte extracts. Mammalian 
oocytes express H4K20me modifying enzymes [54] and 
oocyte-specific factors can dynamically contribute to the 
reprogramming process by assimilation into reprogrammed 
cells [15, 55]. In addition, un-ovulated oocytes are arrested 
in prophase of meiosis I through inhibition of p44/42 MAPK 
phosphorylation [56]. Therefore, it is possible that oocyte 
molecules that are naturally involved in the maintenance 
of oocyte cell cycle arrest could be assimilation into cancer 
cells and mediate tumour reversion.
Induction of primary tumour dormancy represents 
an attractive therapeutic strategy for cancer treatment [57, 
58]. Our data show that AOE reprogramming of cancer 
cells to a quiescent state is initiated early during the extract 
treatment and maintained stably during the development 
of xenografts over time (at least up to 15 months, data 
not shown). Therefore, oocyte extracts may contain 
molecules involved in inducing stable chemoquiescence 
and tumour reversion. Although this study is limited to 
the analysis of tumour reversion in luminal breast cancer 
cells, it highlights the importance of tumour reversion 
approaches based on cell cycle arrest and activation of the 
RB pathway. RB signalling plays a critical role in breast 
cancer and therefore therapeutic strategies that harness this 
pathway have a potential for clinical intervention [59]. 
This is particularly relevant for luminal-type breast cancer 
whereby reactivation of the RB pathway is beneficial for 
the treatment of tumours resistant to endocrine therapies 
[60]. Therefore, together with CDK inhibitors, purified 
molecules from axolotl oocytes could contribute to the 
development of new dormancy-promoting therapies aimed 
to maintain tumours in an asymptomatic state as well as to 
strategies for cancer prevention.
MATERIALS AND METHODS
All cell culture materials were from Invitrogen and 
chemicals from Sigma-Aldrich, unless otherwise stated.
Cell culture and extract treatment
The breast cancer cell line MCF-7 was obtained 
from ATCC and was grown in RPMI-1640 medium 
supplemented with 10% foetal calf serum (FCS), 1% 
Penicillin/Streptomycin (Pen/Strep), 1% L-Glutamine, 
1% sodium pyruvate, 1% non-essential amino acids. Cell 
line identity was validated by genotyping (Bio-Synthesis 
Inc) and cells were regularly checked for mycoplasma 
contamination using the EZ-PCR Mycoplasma 
Test Kit (Geneflow Ltd). For extract treatment, cell 
permeabilisation was performed as previously reported 
[20, 55]. Briefly, cell suspensions (2×106 cells/ml) were 
treated with 20 μg/ml digitonin in PB buffer (170 mM 
potassium gluconate, 5 mM KCl, 2 mM MgCl2, 1 mM 
KH2PO4, 1 mM EGTA, 20 mM Hepes, supplemented 
with 1:5,000 dilution of Protease Inhibitor Cocktail, pH 
7.25) for 1-2 min on ice. Cells were washed in cold PB 
buffer and permeabilisation was assessed by staining with 
propidium iodide (PI). AOE were prepared from mature 
females as described previously [55]. Permeabilised cells 
were added either to growth medium (untreated group) 
or oocyte extracts (5,000 cells/μl extract) supplemented 
with an energy regenerating system (150 μg/ml creatine 
phosphokinase, 60 mM phosphocreatine, 1mM ATP) 
and incubated at 17°C. After reprogramming, cells were 
plated in growth medium overnight. On the next day, 
cells were collected and viability assessed by trypan blue 
stain. Only cultures with more than 95% viability were 
used for injection into immunocompromised mice or other 
characterisation studies. For epigenetics studies, AOE 
was pre-treated with 10 μM Daminozide (DAM) (Tocris 
Bioscience) or 10 μM A-196 (kindly provided by SGC, 
www.thesgc.org) 2 hours at 17°C. The inhibitors were 
maintained in both AOE and buffer control during the 6 
hours reprogramming. After this, cells were washed and 
incubated in culture medium for analysis at 12 hours.
Tumour xenografts
Female MF1 nude mice (Harlan-Olac) were 
injected sub-cutaneously into the left flank with 1.5×106 
MCF-7 cells (untreated and AOE-treated) in a volume 
of 200μl Matrigel. 17-beta-estradiol pellets (0.1mg, 60-
day release; Innovative Research of America, US) were 
implanted subcutaneously into the scruff of each mouse 
(n=6). Tumour dimensions were monitored twice weekly 
by calliper measurements. For BrdU incorporation 
experiments, BrdU (10 mg/ml) was injected at a dose 
of 150mg/kg via intraperitoneal injection 60 minutes 
before sacrifice. At termination (11 weeks), tumours were 
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excised, stored in RNAlater (Thermo Scientific) or fixed 
in formalin and paraffin embedded. The project was run 
under Home Office project PPL 40/2962 with local ethical 
approval. The study adhered to the UK Co-ordinating 
Committee for Cancer Research (UKCCCR) guidelines.
Immunohistochemistry
Histology sections (5 μm) were de-waxed and 
processed for antigen retrieval (citrate buffer pH 6, 
15 min using microwave). Slides were washed with 
PBS and treated with Bloxall blocking solution (Vector 
Laboratories). Slides were then incubated with Mouse 
on Mouse blocking reagent (Vector Laboratories) and 
2.5% normal horse serum (1 hour, RT) before incubation 
with primary antibody at 4°C overnight. This was then 
followed washes with PBS containing 0.1% Tween 20 
and by incubation with secondary antibody for 1 hour at 
RT (ImmPRESS kit, Vector laboratories). After further 
washing, the slides were incubated with DAB for 1-5 
minutes, counterstained with haematoxylin, dehydrated 
and mounted with DPX. For BrdU staining, sections were 
treated with PBS containing 0.25% Triton X-100 and 
0.1% goat serum for 10 min at room temperature (RT) and 
blocked with PBS containing 10% goat serum for 1h at 
RT. After blocking, sections were incubated with 0.02U/
ul DNAse in DNAse buffer (Qiagen) for 10 min at 37°C 
and then washed with PBS 3 times for 10 min at RT before 
incubation with the primary antibody. Tissue section slides 
were observed under a Nikon Eclipse microscope with the 
Nikon NIS-Elements imaging software.
For cell staining, slides were prepared using 
cytospin. After centrifugation, cells were fixed with 4% 
paraformaldehyde and then permeabilised with PBS 
containing 0.1% Triton X-100 for 10 minutes at RT. 
Slides were blocked with PBS containing 5% bovine 
serum albumin (BSA) for 1 hour at RT, followed by 
incubation with primary antibody overnight at 4°C and 
secondary antibody 1 hour at RT. Slides were washed after 
each antibody with PBS containing 0.1% Tween 20 and 
mounted with Vectashield mounting medium containing 
DAPI (Vector Laboratories). Slides were observed under 
a Leica DM5000B microscope with the Leica Application 
Suite software. For image quantification, 3-4 tumours were 
analysed for each treatment group and 5-6 random fields 
of view were analysed with the software Fiji-ImageJ. 
Quantification of images was performed by calculating 
the % of positive cells based on the ratio between the area 
stained by antibodies and the area of counterstained nuclei. 
Antibodies used are listed in Supplementary Table 2.
Gene expression analysis
Total RNA was extracted with the RNeasy Mini Kit 
(Qiagen) and cDNA transcribed with the RT2 First Strand 
Kit (Qiagen). Real-time PCR (qRT-PCR) data analysis was 
performed by using TaqMan® gene expression assays and 
master mix (Applied Biosciences). Assays used are listed 
in Supplementary Table 2. Data analysis was performed 
by using the relative quantification ΔΔCT method with 
normalization to the housekeeping genes RPLP0 which 
was selected after analysis of stability across samples 
with the software BestKeeper [61]. Gene expression of 
tumour xenografts (two biological replicates in technical 
triplicates) was analysed by microarray hybridisation 
using the Illumina HumanHT-12 v4 Expression BeadChip 
array (Source BioScience). The concentration and quality 
of the total RNA was assessed by spectrophotometry and 
using the Agilent Bioanalyser. Samples were normalised 
to 100ng and were processed according to the Illumina 
Whole-Genome Gene Expression Direct Hybridisation 
Assay Guide, using the Ambion Kit: Illumina® 
TotalPrep™-96 RNA Amplification Kit. Qualitative 
& quantitative QCs were performed on the labelled 
cRNA and 1.5ug of labelled cRNA was hybridised to a 
HumanHT-12.v4 Beadchip & scanned by the BeadArray 
Reader. The array intensity data was analysed by the 
Illumina GenomeStudio software v2010.2. All analyses 
reported used the ‘quantile’ normalisation method with 
background correction within GenomeStudio.
Bioinformatics analysis of differentially expressed 
genes was performed using the ArrayMining software 
[62] with the Empirical Bayes moderated t-test method. 
Significant difference in expression was determined 
by FDR corrected p-value from multiple t-tests < 0.05. 
Microarray data were deposited in GEO with accession 
number GSE104383.
Gene ontology analyses were performed using 
the programs AmiGO 2 [63] and REVIGO [64]. The 
gene networks, pathways and functional analyses were 
generated through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.
qiagen.com/ingenuity) [65].
Meta-analysis of published data was performed by 
using the software Venny 2.1.0 (http://bioinfogp.cnb.csic.
es/tools/venny/).
Western blotting
Proteins were extracted with RIPA Buffer (Cell 
Signalling Technology), supplemented with Protease and 
Phosphatase Inhibitor Cocktails for 30 minutes on ice. Cells 
were centrifuged at 12,000 x g for 10 minutes at 4°C and 
protein lysate collected. The protein content was quantified 
using a Qubit Protein Assay Kit (Life Technologies) 
following the manufacturer’s protocol. Proteins were loaded 
into 8-12% polyacrylamide gels (30 μg/lane), separated 
by SDS-PAGE electrophoresis and blotted onto a PVDF 
membrane. Membranes were blocked with 5% BSA and 
then probed overnight at 4°C with primary antibodies. 
Peroxidase conjugated secondary antibodies were incubated 
for 1h at RT. ECL Prime (GE Healthcare) was used to 
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detect chemiluminescence. Membranes were stripped 
with 0.2M glycine, pH 2.8 at 50°C for 30 min followed 
by neutralisation with 0.2M glycine, pH 7.4. Membranes 
were then blocked and re-probed with a control antibody. 
Antibodies used are listed in Supplementary Table 2.
Statistics
Data are expressed as mean ± standard deviation 
(SD) unless otherwise stated. Quantitative RT-PCR 
analyses were analysed by Student’s t-test and One-way 
or Two-way analysis of variance (Anova) followed by 
Bonferroni’s multiple comparison test. Immunostaining 
data were analysed by Mann-Whitney test and One/Two-
way Anova followed by Bonferroni’s multiple comparison 
test. Statistical analyses were performed with GraphPad 
Prism 7 with significance levels set at *p< 0.05, **p<0.01, 
***p<0.001, ****p<0.0001.
Abbreviations
AOE, axolotl oocyte extracts. UN, untreated. GO, 
gene ontology. IPA, ingenuity pathway analysis. mRNA, 
messenger RNA. rRNA, ribosomal RNA. MAPK, mitogen 
activated protein kinase. SAPK/JNK, stress activated 
protein kinase/c-jun N-terminal kinase. AKT, protein 
kinase B. mTOR, mechanistic target of rapamycin. 
ERK, extracellular signal regulated kinase. CDK, cyclin 
dependent kinase. RB, retinoblastoma protein. CDKN1B, 
cyclin dependent kinase inhibitor 1B. EIF2, eukaryotic 
translation initiation factor 2. TOB1, transducer of 
ERBB2, 1. BTG2, BTG anti-proliferation factor 2. 
THBS1, thrombospondin 1. HES1, Hes family BHLH 
transcription factor 1. MLL5, lysine methyltransferase 
2E. JUN, Jun proto-oncogene, AP-1 transcription factor 
subunit. FOS, Fos proto-oncogene, AP-1 transcription 
factor subunit. RPLP0, ribosomal protein lateral stalk 
subunit P0. PHF8, Jumonji C domain-containing histone 
demethylase 1F. SUV420H1/H2, lysine methyltransferase 
5B/5C. DAM, daminozide. FCS, fetal calf serum. PBS, 
phosphate buffered saline. PB, permeabilisation buffer. 
PI, propidium iodide. BrdU, bromodeoxyuridine.RT, room 
temperature. BSA, bovine serum albumin. FDR, false 
discovery rate. SD, standard deviation. qRT-PCR, real 
time quantitative PCR. GEO, gene expression omnibus.
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